For public health emergencies, WHO has a systematic and transparent process for research and development (R&D), including for clinical trials of drugs.
The WHO R&D Blueprint for COVID-19, initiated on 7 January 2020, aims to fast-track the availability of effective tests, vaccines and medicines that can be used to save lives and avert large-scale crises.
7483
世卫组织对使用蒿属植物来预防或治疗疟疾和/或COVID-19的立场是什么？
What is WHO’s position on the use of Artemisia plant material for the prevention or treatment of malaria and/or COVID-19?
7484
最广泛使用的抗疟药物，以青蒿素为基础的联合疗法，是使用从青蒿植物中提取的纯青蒿素化合物制成的。
The most widely used antimalarial treatments, artemisinin-based combination therapies (ACTs), are produced using the pure artemisinin compound extracted from the plant Artemisia annua .
7485
有报道称由蒿属植物制成的产品或提取物（如草药茶和药片）可能对COVID-19有预防或治疗作用。
There have been reports that products or extracts (e.g.
herbal teas or tablets) made from Artemisia plant material may have a preventive or curative effect on COVID-19.
7487
因此，当前证据不支持将青蒿素或青蒿产品或提取物用作治疗COVID-19的抗病毒药物。
However, available in vitro data suggests that purified artemisinin compounds or A. annua plant product or extracts do not have an appreciable effect against COVID-19 at concentrations that could be safely achieved in humans.
7488
世卫组织强烈建议对宣扬此类产品功效的报道要格外小心。
As such, current evidence does not support the use of artemisinins or A. annua products or extracts as an antiviral for COVID-19.
7489
正如 世卫组织立场声明 中所解释的，没有科学证据支持使用非药物形式的蒿属植物来预防或治疗疟疾。
WHO urges extreme caution over reports touting the efficacy of such products.
7490
也没有证据表明，由蒿属植物制成的产品可以预防或治疗COVID-19。
As explained in a WHO position statement , there is no scientific evidence base to support the use of non-pharmaceutical forms of Artemisia for the prevention or treatment of malaria.